Partial seizure

Active Ingredient: Oxcarbazepine

Indication for Oxcarbazepine

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Oxcarbazepine is indicated for the treatment of partial seizures with or without secondarily generalised tonicclonic seizures.

Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in adults and in children of 6 years of age and above.

For this indication, competent medicine agencies globally authorize below treatments:

8-46 mg/kg in 2 divided doses daily

Route of admnistration

Oral

Defined daily dose

8 - 46 mg per kg of body weight

Dosage regimen

From 4 To 23 mg per kg of body weight 2 time(s) per day every day

Loading dose

8 mg per kg of body weight

Detailed description

Recommended initial dose: In mono- and adjunctive therapy, Oxcarbazepine Mylan should be initiated with a dose of 8-10 mg/kg/day given in 2 divided doses.

Maintenance dose: In adjunctive therapy trials, a maintenance dose of 30-46 mg/kg/day, achieved over two weeks, is shown to be effective and well tolerated in children. Therapeutic effects were seen at a median maintenance dose of approximately 30
mg/kg/day.

Maximum recommended dose: If clinically indicated, the dose may be increased by a maximum of 10 mg/kg/day at approximately weekly intervals from the starting dose, to a maximum dose of 46 mg/kg/day, to achieve the desired clinical response.

Oxcarbazepine is recommended for use in children of 6 years of age and above. Safety and efficacy have been evaluated in controlled clinical trials involving approximately 230 children aged less than 6 years (down to 1 month).

Oxcarbazepine is not recommended in children aged less than 6 years since safety and efficacy have not been adequately demonstrated.

All the above dosing recommendations are based on the doses studied in clinical trials. However, lower initiation doses may be considered where appropriate.

Dosage considerations

Oxcarbazepine can be taken with or without food.

Active ingredient

Oxcarbazepine

The pharmacological activity of oxcarbazepine is primarily exerted through the metabolite (MHD). The mechanism of action of oxcarbazepine and MHD is thought to be mainly based on the blockade of voltage-sensitive sodium channels.

Read more about Oxcarbazepine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.